JP2015504677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504677A5 JP2015504677A5 JP2014552323A JP2014552323A JP2015504677A5 JP 2015504677 A5 JP2015504677 A5 JP 2015504677A5 JP 2014552323 A JP2014552323 A JP 2014552323A JP 2014552323 A JP2014552323 A JP 2014552323A JP 2015504677 A5 JP2015504677 A5 JP 2015504677A5
- Authority
- JP
- Japan
- Prior art keywords
- tcf
- biomarker
- level
- subject
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586672P | 2012-01-13 | 2012-01-13 | |
| US61/586,672 | 2012-01-13 | ||
| PCT/US2013/021197 WO2013106686A1 (en) | 2012-01-13 | 2013-01-11 | Biomarkers for the treatment of hepatocellular carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504677A JP2015504677A (ja) | 2015-02-16 |
| JP2015504677A5 true JP2015504677A5 (enExample) | 2016-03-03 |
Family
ID=47604231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552323A Pending JP2015504677A (ja) | 2012-01-13 | 2013-01-11 | 肝細胞癌治療のためのバイオマーカー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8901110B2 (enExample) |
| EP (1) | EP2802877A1 (enExample) |
| JP (1) | JP2015504677A (enExample) |
| CN (1) | CN104737021A (enExample) |
| AU (1) | AU2013202104B2 (enExample) |
| CA (1) | CA2871535A1 (enExample) |
| MX (1) | MX2014008388A (enExample) |
| WO (1) | WO2013106686A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035389T2 (en) | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| RU2611007C2 (ru) | 2011-03-11 | 2017-02-17 | Селджин Корпорейшн | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение |
| WO2014039421A1 (en) | 2012-09-04 | 2014-03-13 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| WO2015085172A2 (en) * | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| CN103645259B (zh) * | 2013-12-12 | 2015-03-11 | 深圳海王药业有限公司 | 一种同时测定泊马度胺及其有关物质的方法 |
| JP2017533727A (ja) * | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| CN108048568B (zh) * | 2017-12-25 | 2021-02-02 | 贵州省人民医院 | Plcd4基因作为胃腺癌转移诊断标志物的用途 |
| CN109266747B (zh) * | 2018-09-21 | 2021-07-27 | 中国医学科学院北京协和医院 | 与i型神经纤维瘤合并脊柱畸形病相关gpr56及其应用 |
| CN113194934B (zh) * | 2018-10-14 | 2025-02-25 | 蓝腾制药公司 | 使用隐陡头菌素和生物标志物治疗实体肿瘤癌症的方法 |
| CA3121273A1 (en) * | 2018-11-29 | 2020-06-04 | Trillium Therapeutics Inc. | Biomarkers for cd47 blockade therapy |
| CN116064810A (zh) * | 2022-11-10 | 2023-05-05 | 杭州医学院 | CD24作为Hippo通路失活亚型肝细胞癌生物标志物的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1166651C (zh) * | 2001-06-08 | 2004-09-15 | 北京大学药学院 | 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物 |
| US7803783B2 (en) * | 2002-12-06 | 2010-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Use of WNT inhibitors to augment therapeutic index of chemotherapy |
| WO2011109237A2 (en) * | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
-
2013
- 2013-01-11 US US13/740,012 patent/US8901110B2/en active Active
- 2013-01-11 WO PCT/US2013/021197 patent/WO2013106686A1/en not_active Ceased
- 2013-01-11 JP JP2014552323A patent/JP2015504677A/ja active Pending
- 2013-01-11 AU AU2013202104A patent/AU2013202104B2/en not_active Ceased
- 2013-01-11 CA CA2871535A patent/CA2871535A1/en not_active Withdrawn
- 2013-01-11 MX MX2014008388A patent/MX2014008388A/es unknown
- 2013-01-11 EP EP13701319.9A patent/EP2802877A1/en not_active Withdrawn
- 2013-01-11 CN CN201380014334.8A patent/CN104737021A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Voigt et al. | Serotonin controlling feeding and satiety | |
| Bermudez et al. | Gli1 mediates lung cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell activation | |
| Newman et al. | Leptin–cytokine crosstalk in breast cancer | |
| IL278381B1 (en) | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers | |
| JP2016500110A5 (enExample) | ||
| JP2014516552A5 (enExample) | ||
| Trikha et al. | E2f3 in tumor macrophages promotes lung metastasis | |
| Wang et al. | The non-canonical role of vascular endothelial growth factor-C axis in cancer progression | |
| Lin et al. | Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy? | |
| JP2012093361A5 (enExample) | ||
| Yang et al. | Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer | |
| JP2017524130A5 (enExample) | ||
| JP2011501176A5 (enExample) | ||
| IL247111B2 (en) | Preventive or therapeutic agent for kidney disease | |
| JP2014144959A5 (enExample) | ||
| Yue et al. | Rnd3 haploinsufficient mice are predisposed to hemodynamic stress and develop apoptotic cardiomyopathy with heart failure | |
| WO2015100459A3 (en) | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies | |
| RU2016107954A (ru) | Способы идентификации и прогнозирования риска сердечно-сосудистого события или заболевания, или смертельного исхода, способы оценки тяжести и мониторинга сердечно-сосудистого события или заболевания, способ мониторинга эффективности терапии | |
| MX2014008388A (es) | Biomarcadores para el tratamiento de carcinoma hepatocelular. | |
| Hiwasa | Association of serum antibody levels against TUBB2C with diabetes and cerebral infarction | |
| Aryal et al. | A switch in the dynamics of intra-platelet VEGF-A from cancer to the later phase of liver regeneration after partial hepatectomy in humans | |
| Montano-Loza | Skeletal muscle abnormalities and outcomes after liver transplantation | |
| He et al. | Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients | |
| Kato et al. | Lactate dehydrogenase and hemolysis in sickle cell disease | |
| MX380889B (es) | Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson. |